Last reviewed · How we verify
GamTBvac
GamTBvac is a therapeutic tuberculosis vaccine that stimulates immune responses against Mycobacterium tuberculosis antigens to enhance host immunity and control infection.
GamTBvac is a therapeutic tuberculosis vaccine that stimulates immune responses against Mycobacterium tuberculosis antigens to enhance host immunity and control infection. Used for Tuberculosis (active disease, as adjunct to standard chemotherapy), Latent tuberculosis infection.
At a glance
| Generic name | GamTBvac |
|---|---|
| Sponsor | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation |
| Drug class | Therapeutic vaccine |
| Target | Mycobacterium tuberculosis antigens |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
GamTBvac is a recombinant viral vector-based vaccine designed to boost cellular and humoral immune responses in tuberculosis patients. It uses a viral platform to deliver TB antigens, aiming to enhance the body's ability to control active or latent TB infection. The vaccine is intended for use as an adjunctive immunotherapy in combination with standard anti-TB chemotherapy.
Approved indications
- Tuberculosis (active disease, as adjunct to standard chemotherapy)
- Latent tuberculosis infection
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Study of the Safety and Efficacy of the Subunit Recombinant Tuberculosis Vaccine GamTBvac (PHASE3)
- Phase II Clinical Trial of Safety and Immunogenicity of Recombinant Subunit Tuberculosis Vaccine GamTBvac (PHASE2)
- Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine "GamTBvac" Against the Tuberculosis. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: